8-K
filed November 28, 2023, 6:59 PM ET
ticker IBIO
CIK 0001420720
other material
confidence high
sentiment negative
materiality 0.85
iBio effects 1-for-20 reverse stock split, reduces outstanding shares from 28.1M to 1.4M
iBio, Inc.
- Reverse stock split at 1:20 effective 12:01 a.m. ET Nov 29, 2023; shares continue trading as IBIO.
- Outstanding shares reduced from 28,100,733 to 1,405,036; fractional shareholders to receive cash.
- Stockholders approved reverse split with 5.8M for vs 5.2M against at Nov 27 annual meeting.
- Also adopted 2023 Omnibus Incentive Plan and elected directors Clark and Sender.
- New CUSIP number is 451033708; transfer agent Continental Stock Trust handling exchanges.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
iBio, Inc.: Certificate of Incorporation amended to effect a 1-for-20 reverse stock split, effective November 29, 2023 (effective 2023-11-28).
- Change
- charter amendment
- Effective
- 2023-11-28
Exact text from the filing
On November 28, 2023, the Company filed an amendment to the Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the reverse stock split, with an effective time of 12:01 a.m. Eastern Time on November 29, 2023 (the “Reverse Stock Split”).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
iBio, Inc. shareholders approved Approval of adjournment of the 2023 Annual Meeting at the 2023-11-27 meeting.
- Outcome
- passed
- Meeting
- 2023-11-27
Exact text from the filing
The stockholders approved the adjournment of the 2023 Annual Meeting, based on the votes set forth below; however, an adjournment was not needed as Proposals 4 and 5 received a sufficient number of votes for approval.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
iBio, Inc. shareholders approved Approval of amendment to Certificate of Incorporation for reverse stock split range of 1-for-5 to 1-for-20 at the 2023-11-27 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-11-27
Exact text from the filing
The stockholders approved an amendment to the Company’s Certificate of Incorporation, at a ratio of 1-for-5 to 1-for-20 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board and included in a public announcement.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
iBio, Inc. shareholders approved Advisory vote on executive compensation at the 2023-11-27 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-11-27
Exact text from the filing
The stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers ("say-on-pay"), as disclosed in the Definitive Proxy Statement.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
iBio, Inc. shareholders approved Ratification of CohnReznick LLP as independent registered public accounting firm at the 2023-11-27 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-11-27
Exact text from the filing
The stockholders ratified the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the year ending June 30, 2024 based on the votes set forth below:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
iBio, Inc. shareholders approved Election of two Class III directors at the 2023-11-27 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-11-27
Exact text from the filing
The following two (2) nominees named as Class III directors of the Company’s Board of Directors, each to serve a three-year term expiring at the 2026 Annual Meeting of Stockholders and until such director’s successor is duly elected and qualified, were elected with the following votes:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
iBio, Inc. shareholders approved Adoption of the 2023 Plan at the 2023-11-27 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-11-27
Exact text from the filing
The stockholders approved the adoption of the 2023 Plan.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.